Welcome to the REMS Programs Administered by Bristol Myers Squibb
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID® (thalidomide), POMALYST® (pomalidomide), REVLIMID® (lenalidomide) and generic lenalidomide. The THALOMID REMS® program, Lenalidomide REMS program and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.
If you would like to obtain more information about any of the Bristol Myers Squibb-administered REMS programs, please click on the program name below:
To complete a REMS related task, please select the appropriate option from below: